AI-081 is a differentiated bispecific antibody with robust cooperative interactions between PD1 and VEGFDosing of first patient in BIPAVE-001 ...

Replimune's BLA submission and promising pipeline drugs are set to impact the global melanoma therapeutics market. Read more ...

Adagene Inc. (NASDAQ:ADAG – Get Free Report) was the target of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 1,500 shares, a ...

The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...

The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...

On November 21, 2024, Replimune Group, Inc. (NASDAQ: REPL) made significant strides in the advancement of its lead product candidate, RP1. The company announced the submission of a biologics license ...

Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive ...

Ever since The Witcher 4 (Codenamed Polaris) was announced all the way back in 2022, fans have been on tenterhooks waiting - pleading - for more concrete information on the upcoming fantasy RPG.

Through a differentiated strategy and forward-thinking approach, the company has successfully developed and launched the globally first cancer immunotherapy bispecific antibody, cadonilimab (PD-1/CTLA ...

And frankly, we're more than ready to bring out the silver swords again. With the Witcher 4 only entering pre-production in mid-2022, the next Witcher saga is still in the distant future ...

I also reached out to our staffers and contributors to get their recommendations for the best deodorants and anti-perspirants for daily use and for workouts. Update on November 14, 2024 ...